C4X Discovery Holdings plc, a British drug discovery company, is making waves in the industry with its innovative platforms and promising product pipeline. At the core of the company's technology is Taxonomy3, an in silico platform that uses proprietary mathematical algorithms to analyze genetic data with unparalleled accuracy. Additionally, C4X's Conformetrix technology allows medicinal chemists to measure the 3D shape of free drug molecules from experimental data, providing crucial insights into their behavior and physical properties. The company's 4Sight platform uses virtual reality to visualize 4D molecules, giving scientists a comprehensive understanding of their complex molecular shape data. C4X has several promising products in its pipeline, including Orexin-1, a receptor antagonist for the treatment of addictive disorders; NRF-2 activator for inflammatory diseases; IL-17A inhibitor for inflammation and autoimmune diseases; a4ß7 integrin inhibitors for inflammatory bowel disease; and MALT-1 inhibitors for hematological cancer. C4X has established partnerships with industry giants such as Sanofi, Therapeutics, Horizon, LifeArc, INDIVIOR, and Phoremost. Formerly known as Schosween 24 plc, C4X changed its name in October 2014. The company was founded in 2007 and is headquartered in Manchester, United Kingdom. With its cutting-edge technology and strong partnerships, C4X is sure to have a bright future in the drug discovery industry.
C4X Discovery's ticker is C4XD.L
The company's shares trade on the LSE stock exchange
They are based in Manchester, England
There are 11-50 employees working at C4X Discovery
It is https://www.c4xdiscovery.com/
C4X Discovery is in the Healthcare sector
C4X Discovery is in the Biotechnology industry
The following five companies are C4X Discovery's industry peers: